Trevena (NASDAQ: TRVN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.100 | ||||||
REV | 20.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Trevena (NASDAQ: TRVN) through any online brokerage.
Other companies in Trevena’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Orchard Therapeutics (NASDAQ:ORTX), 89bio (NASDAQ:ETNB), Lumos Pharma (NASDAQ:LUMO) and Infinity Pharmaceuticals (NASDAQ:INFI).
The latest price target for Trevena (NASDAQ: TRVN) was reported by HC Wainwright & Co. on Thursday, May 12, 2022. The analyst firm set a price target for 3.50 expecting TRVN to rise to within 12 months (a possible 745.41% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Trevena (NASDAQ: TRVN) is $0.414 last updated June 30, 2022, 8:00 PM UTC.
There are no upcoming dividends for Trevena.
Trevena’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Trevena.
Trevena is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.